Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 110

Results For "NDA"

5518 News Found

EMA moves to cut animal testing with “virtual control groups” in preclinical research
Policy | April 03, 2026

EMA moves to cut animal testing with “virtual control groups” in preclinical research

The approach, which could significantly reduce the number of rats used in certain dose-range finding studies


Molbio’s digital radiology arm secures CE MDR certification for its medical imaging portfolio
Medical Device | April 02, 2026

Molbio’s digital radiology arm secures CE MDR certification for its medical imaging portfolio

Certification by TÜV SÜD Product Service GmbH reinforces the company's commitment to globally benchmarked standards in safety, quality, and performance


Marksans Pharma receives USFDA approval for Benzonatate capsules
Drug Approval | April 02, 2026

Marksans Pharma receives USFDA approval for Benzonatate capsules

Benzonatate is a non-narcotic antitussive that numbs stretch receptors in the respiratory tract


Alembic Pharmaceuticals partners with Enthral.ai for learning and training management of its 9000+ learners
News | April 02, 2026

Alembic Pharmaceuticals partners with Enthral.ai for learning and training management of its 9000+ learners

Enthral.ai’s platform integrates AI-driven capabilities with compliance-first architecture, enabling automated training workflows


D2C nutrition brand BeastLife raises Rs 20 crore at Rs 320 crore valuation from GVFL and Equentis
News | April 02, 2026

D2C nutrition brand BeastLife raises Rs 20 crore at Rs 320 crore valuation from GVFL and Equentis

The company has achieved a turnover of around Rs 100 crore in FY 2025–26 and aims to achieve a turnover of Rs 500 crore in next three years


Vyome Holdings bolsters financial position to support VT-1953 pivotal study through 2027
Biotech | April 02, 2026

Vyome Holdings bolsters financial position to support VT-1953 pivotal study through 2027

As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million


FDA okays Eli Lilly’s new weight-loss pill, expanding options for millions
News | April 02, 2026

FDA okays Eli Lilly’s new weight-loss pill, expanding options for millions

The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants


Agilent opens new customer experience center in Mumbai
Technology | April 02, 2026

Agilent opens new customer experience center in Mumbai

The center brings together hands on technology demonstrations, application expertise, and commercial operations


Biogen to buy Apellis Pharmaceuticals for $5.6B in rare disease and immunology push
News | April 02, 2026

Biogen to buy Apellis Pharmaceuticals for $5.6B in rare disease and immunology push

The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio


Middle East disruption hits thousands of global clinical trials, Phesi warns
Clinical Trials | April 02, 2026

Middle East disruption hits thousands of global clinical trials, Phesi warns

The impact on Phase III trials is particularly significant, as these later-stage studies involve larger, committed patient populations and represent years of investment